Reactivation of pulmonary tuberculosis in a patient with rheumatoid arthritis during treatment with IL-1 receptor antagonists (anakinra)

Journal of Clinical Rheumatology

Volumn 13, Issue 4, 2007, Pages 219-220

  Settas, Lucas D ^a   Tsimirikas, George ^a   Vosvotekas, George ^a   Triantafyllidou, Eva ^a   Nicolaides, Paul ^a  

^a AHEPA UNIVERSITY HOSPITAL   (Greece)

Author keywords

Anakinra; IL 1 antagonist; Pulmonary tuberculosis

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CIPROFLOXACIN; ISONIAZID; METHOTREXATE; PREDNISOLONE; PYRAZINAMIDE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RIFAMPICIN;

AGED; ARTICLE; CASE REPORT; CHEST INFECTION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; HUMAN; LUNG INFILTRATE; LUNG TUBERCULOSIS; MALE; MONOTHERAPY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; SIDE EFFECT; SPUTUM CYTODIAGNOSIS; THORAX RADIOGRAPHY;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; RECURRENCE; TUBERCULOSIS, PULMONARY;

EID: 34548413549     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/RHU.0b013e31812e00a1     Document Type: Article

References (8)

1. Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents, specifically tumour necrosis factor α (TNFα) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases. Ann Rheum Dis. 2005;64:iv2-iv14.
2. Winthrop KL. Update on tuberculosis and other opportunistic infections associated with drugs blocking tumour necrosis factor α. Ann Rheum Dis. 2005;64:iv29-iv30.
3. Botsios C. Safety of tumour necrosis factor and interleukin-1 blocking agents in rheumatic diseases. Autoimmun Rev. 2005;4:162-170.
4. Fleishmann RM. Safety of anakinra, a recombinant interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis and comparison to anti-TNF-agents. Clin Exp Rheumatol. 2002;20:S35-S41.
5. Keane J. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology. 2005;44:714-720.
6. Ehlers S. Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept? Clin Infec Dis. 2005;41:s199-s203.
7. Ledingham J, Wilkinson C, Deighton C. British Thoracic Society (BTS) recommendations for assessing risk and managing tuberculosis in patients due to start anti-TNF-α treatments. Rheumatology. 2005;44:1205-1206.
8. Kineret (Anakinra). Product Monograph. Amgen Inc. 2002;1-47.